NO20080649L - Forbindelser omfattende DMXAA for behandling av kreft - Google Patents

Forbindelser omfattende DMXAA for behandling av kreft

Info

Publication number
NO20080649L
NO20080649L NO20080649A NO20080649A NO20080649L NO 20080649 L NO20080649 L NO 20080649L NO 20080649 A NO20080649 A NO 20080649A NO 20080649 A NO20080649 A NO 20080649A NO 20080649 L NO20080649 L NO 20080649L
Authority
NO
Norway
Prior art keywords
compounds
dmxaa
combinations
cancer
treatment
Prior art date
Application number
NO20080649A
Other languages
English (en)
Norwegian (no)
Inventor
Gail Rowlinson-Busza
Colin Green
Lloyd Kelland
Original Assignee
Antisoma Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0517386A external-priority patent/GB0517386D0/en
Priority claimed from GB0604114A external-priority patent/GB0604114D0/en
Application filed by Antisoma Plc filed Critical Antisoma Plc
Publication of NO20080649L publication Critical patent/NO20080649L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20080649A 2005-08-26 2008-02-06 Forbindelser omfattende DMXAA for behandling av kreft NO20080649L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0517386A GB0517386D0 (en) 2005-08-26 2005-08-26 Combinations for the treatment of cancer
GB0604114A GB0604114D0 (en) 2006-03-02 2006-03-02 Combinations for the treatment of cancer
PCT/GB2006/003196 WO2007023302A1 (en) 2005-08-26 2006-08-25 Combinations comprising dmxaa for the treatment of cancer

Publications (1)

Publication Number Publication Date
NO20080649L true NO20080649L (no) 2008-05-26

Family

ID=37429252

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080649A NO20080649L (no) 2005-08-26 2008-02-06 Forbindelser omfattende DMXAA for behandling av kreft

Country Status (14)

Country Link
US (1) US20100297112A1 (pt)
EP (1) EP1917011A1 (pt)
JP (1) JP2009506019A (pt)
KR (1) KR20080047402A (pt)
AU (1) AU2006283371A1 (pt)
BR (1) BRPI0614965A2 (pt)
CA (1) CA2620436A1 (pt)
EC (1) ECSP088243A (pt)
IL (1) IL189376A0 (pt)
MA (1) MA29786B1 (pt)
NO (1) NO20080649L (pt)
RU (1) RU2404764C2 (pt)
TN (1) TNSN08056A1 (pt)
WO (1) WO2007023302A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002009700A1 (en) 2000-07-28 2002-02-07 Cancer Research Technology Limited Cancer treatment by combination therapy
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
GB2386836B (en) 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
GB2394658A (en) 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
JP2011506455A (ja) * 2007-12-13 2011-03-03 ノバルティス アーゲー 癌を処置するための治療薬の組み合わせ剤
KR102216772B1 (ko) * 2018-05-18 2021-02-17 주식회사 종근당 혈관차단제 및 탁산 화합물을 포함하는 암 예방 또는 치료용 조성물

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3655470A (en) * 1969-03-29 1972-04-11 Toa Gosei Chem Ind Process for the production of a foamed thermoplastic resin sheet
FR2516922A1 (fr) * 1981-11-25 1983-05-27 Lipha Acides (oxo-4-4h-(1)-benzopyran-8-yl) alcanoiques, sels et derives, preparation et medicament les contenant
DE3587500T2 (de) * 1984-12-04 1993-12-16 Lilly Co Eli Tumorbehandlung bei Säugetieren.
US4704355A (en) * 1985-03-27 1987-11-03 New Horizons Diagnostics Corporation Assay utilizing ATP encapsulated within liposome particles
US5281620A (en) * 1986-12-23 1994-01-25 Cancer Research Campaign Technology Limited Compounds having antitumor and antibacterial properties
US5126129A (en) * 1988-05-23 1992-06-30 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Cancer therapy using interleukin-2 and flavone compounds
US5620875A (en) * 1995-02-17 1997-04-15 University Of Portland Transfer of taxol from yew tree cuttings into a culture medium over time
US5863904A (en) * 1995-09-26 1999-01-26 The University Of Michigan Methods for treating cancers and restenosis with P21
EP0961617A4 (en) * 1996-12-13 2002-08-07 Lilly Co Eli LEUKOTRINE ANTAGONISTS FOR TREATING FOCAL BRAIN CHEMISTRY
HUP9904672A2 (hu) * 1997-03-21 2000-05-28 Eli Lilly And Co. Szájüregi laphámrák ellen alkalmazható leukotrién antagonisták
US6174873B1 (en) * 1998-11-04 2001-01-16 Supergen, Inc. Oral administration of adenosine analogs
DK1033364T3 (da) * 1999-03-01 2005-06-06 Pfizer Prod Inc Cyanholdige oxamidsyrer og -derivater som thyroideareceptorligander
DE60027719T2 (de) * 1999-06-14 2007-04-26 Cancer Research Technology Ltd. Krebstherapie
US6806257B1 (en) * 1999-10-20 2004-10-19 Board Of Trustees Of Southern Illinois University Flavones as inducible nitric oxide synthase inhibitors, cyclooxygenase-2 inhibitors and potassium channel activators
EP1259237A4 (en) * 2000-02-17 2004-07-28 Merck & Co Inc TREATMENT OR PREVENTION OF PROSTATE CANCER USING A SELECTIVE COX-2 INHIBITOR MEDICINE
JP2001247459A (ja) * 2000-03-03 2001-09-11 Oakland Uniservices Ltd 癌の組み合わせ療法
WO2002009700A1 (en) * 2000-07-28 2002-02-07 Cancer Research Technology Limited Cancer treatment by combination therapy
GB0121285D0 (en) * 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
GB2386836B (en) * 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
GB2394658A (en) * 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
CA2523260A1 (en) * 2003-04-21 2004-11-04 Archemix Corporation Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
GB0321999D0 (en) * 2003-09-19 2003-10-22 Cancer Rec Tech Ltd Anti-cancer combinations

Also Published As

Publication number Publication date
TNSN08056A1 (en) 2009-07-14
RU2404764C2 (ru) 2010-11-27
IL189376A0 (en) 2008-06-05
EP1917011A1 (en) 2008-05-07
JP2009506019A (ja) 2009-02-12
AU2006283371A1 (en) 2007-03-01
ECSP088243A (es) 2008-08-29
CA2620436A1 (en) 2007-03-01
BRPI0614965A2 (pt) 2016-09-13
KR20080047402A (ko) 2008-05-28
MA29786B1 (fr) 2008-09-01
US20100297112A1 (en) 2010-11-25
RU2008111492A (ru) 2009-10-10
WO2007023302A1 (en) 2007-03-01

Similar Documents

Publication Publication Date Title
NO20080649L (no) Forbindelser omfattende DMXAA for behandling av kreft
CY1122476T1 (el) Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (τfρι)
UY37223A (es) Anticuerpos de p-caderina
EA200702064A1 (ru) Новое анти-plgf антитело
NO20092360L (no) Nye antiproliferasjonsantistoffer
NO20063193L (no) Fusjonerte pyrrolokarbazoler og fremgangsmater for fremstilling derav
DE60328108D1 (de) Iscom-zubereitung und ihre verwendung
NO20076046L (no) Bindemidler
ATE362932T1 (de) Azaindolverbindungen als kinaseinhibitoren
EA200501430A1 (ru) Лиганды каннабиноидных рецепторов и их применение
TW200740844A (en) Novel MAdCAM antibodies
NO20033950D0 (no) N¶rende farmasöytisk preparat omfattende polyfenoler og anvendelse i behandling av kreft
ATE368662T1 (de) Piperidinyl-thiazol-carbonsäure-derivate als angiogenesis inhibitoren
BRPI0407999A (pt) compostos heteroaromáticos fundidos como inibidores do fator de transformação do crescimento (tgf)
HK1071066A1 (en) Synergistic association of (-)- gossypol with docetaxel or paclitaxel for cancer treatment
PL410219A1 (pl) Kompozycja zawierająca koniugat leku obejmujący pochodne kalicheamycyny i przeciwciało, oraz kompozycja farmaceutyczna ją zawierająca
DE60028970D1 (de) An her2 bindende peptidverbindungen
ATE406156T1 (de) Ajulemische säure zur krebsbehandlung
ATE370139T1 (de) Pyrazolopyridin derivate als tgf beta hemmstoffe zur behandlung von krebs
UA102867C2 (uk) Антитіла до cxcr4 та їх застосування у лікуванні раку
BR0211502A (pt) Derivados de ácido acético de indano e seu uso como agentes farmacêuticos, intermediários, e método de preparação
NO20063062L (no) Imidazolderivater, fremgangsmate for fremstilling og anvendelse av disse
UA92025C2 (en) Indole compounds
MX2009009926A (es) Anticuerpo tumor-especifico humano monoclonal.
ATE485261T1 (de) Salicylsäurederivate

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application